Abstract
BACKGROUND Low-intensity focused ultrasound stimulation (LIFUS) has recently emerged as a promising neuromodulation tool for certain neuropsychiatric diseases. However, its safety and feasibility in stroke patients remains unknown. Intensity is a critical safety parameter for LIFUS. We aimed to determine the maximum safe and tolerable intensity of LIFUS in stroke patients, and to explore its effect on upper-extremity motor learning and corticospinal excitability.
METHODS Subjects with first-ever stroke participated in this Phase I study. We adopted the classic 3+3 dose-escalation paradigm to sham/0, 1, 2, 4, 6, and 8 W/cm2 spatial-peak pulse-average intensity (ISPPA, estimated in-vivo transcranial value; LOW: sham/0, 1 and 2 W/cm2, HIGH: 4, 6 and 8 W/cm2). Stopping rules (dose limiting toxicities) were pre-defined: ≥2nd-degree scalp burn, clinical seizures, ≥20% topical apparent diffusion coefficient change, or participant discontinuation due to any reason. A 12-minute LIFUS was applied over the ipsilesional motor cortex while participants were concurrently practicing three blocks of motor sequence learning (MSL) task using the affected hand. We collected the occurrences of pre-defined adverse events, post-minus-pre improvements in MSL response time, and post-minus-pre differences in corticospinal excitability quantified by motor evoked potentials.
RESULTS ISPPA was escalated to 8 W/cm2 with eighteen stroke participants without meeting stopping rules. Compared to the LOW, the HIGH performed significantly better on the MSL (24.7±13.3% vs. 13.2±10.9%, p=0.01). Similarly, the HIGH also showed signs of increased corticospinal excitability (32.0±34.3% vs. 12.9±48.0%) but did not reach significance, p=0.53.
CONCLUSIONS Our Phase I safety study suggests that a single session of 12-minute LIFUS up to 8 W/cm2 ISPPA is safe and feasible in stroke patients. Higher LIFUS intensities can induce greater MSL retention. The next logical step is to conduct a Phase II study to further test the efficacy of LIFUS and monitor its safety profiles in stroke patients.
REGISTRATION URL: https://www.clinicaltrials.gov; Unique identifier: NCT05016531
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05016531
Funding Statement
This study was funded by the American Heart Association Innovative Project Award (20IPA35360039, WF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Duke University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The present study is supported by the American Heart Association (AHA) and will adhere to the data sharing policies of AHA.